Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
Explore this paper's citation graph
- Type
- article
- Published
- 2009-02-01
- Cited by
- 1
- References
- 27
- Access
- Open access
- OpenAlex
- https://openalex.org/W2254126652
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:204094616
Keywords
Erlotinib, Gefitinib, Medicine, Lung cancer, Erlotinib Hydrochloride
References
- Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers.
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
- Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
- Risk of cancer in women receiving hormone replacement therapy
- Estrogen replacement therapy and risk of lung cancer
- Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
- Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
- Hormonal factors and risk of lung cancer among women?
- Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
- Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
- A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.
- Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
- Hormone replacement therapy is associated with decreased survival in women with lung cancer.
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
- Effects of Smoking on the Pharmacokinetics of Erlotinib
- ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
- An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer.
- EGF Receptor Gene Mutations Are Common in Lung Cancers From “Never Smokers” and Are Associated With Sensitivity of Tumors to Gefitinib and Erlotinib
- Erlotinib in Previously Treated Non-Small-Cell Lung Cancer
Cited by
Related papers
No related papers recorded.